and hybrid academic/community settings (U.S.) assessed the role of clonality assays in standard practice, based on evidence-based peer-reviewed literature and the experience of dermatopathologists in practice. This paper presents the self-reported experiences and practice patterns of attendees at the 53rd Annual Meeting of the ASDP who participated in a survey and a focused review of the literature on the utility of clonality assays in the evaluation and management of LPDs.
| MATERIALS AND METHODS

| Criteria development process
The AUC task force met to divide cutaneous LPDs into B-cell and T- 
| Literature review
The literature was searched between 1995 and 2016 and only studies in the English language were included. Overlapping studies were removed. Case series of n ≥ 3 were included if no other evidence was available.
| ASDP membership survey responses
Solicitation of ASDP member audience experiences was performed using audience response (AR) technology. Fourteen questions on practice patterns and decision making related to the use of clonality assays in the evaluation and diagnosis of LPDs were posed to attendees at the 53rd Annual ASDP meeting in Chicago on October 27, 2016. The PollEverywhere application was used to present the survey questions which offered multiple choice options. Participants selected the most appropriate response using their mobile devices and the responses were recorded and displayed in real-time during the session ( Table 1 ). The audience consisted of 144 dermatopathologists, dermatologists, pathologists and trainees.
3 | RESULTS
| Literature review: B-cell LPD
There were 20 relevant papers for B-cell LPD (Table 2) . [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Six papers examined cutaneous B-cell lymphoma (CBCL) in general, 8, 10, 11, 13, 16, 17 4 were specific for marginal zone lymphoma (MZL), 9, 12, 19, 20 1 specific for follicle center lymphoma (FCL), 21 Three papers examined the clonality status in LBCL-LT. 8, 10, 13 One paper examined intravascular lymphomas 14 and 1 paper examined the scenario of new lymphoid infiltrates in patients with known previous diagnoses of CBCL 11 and those with a known previous clone.
11
One paper examined secondary cutaneous involvement by systemic lymphomas. 17 There were no papers that examined lesions that were clinically concerning for lymphoma but were histologically benign, solitary lesions or eruptions which had a B-cell predominant lymphoid infiltrate, and cases with an unknown history but with pathology that was consistent with lymphoma.
| T-cell LPD
There were 40 relevant papers for T-cell LPD (Table 3) . Sixteen papers examined CTCL in general. 22 The scenario of "clinically concerning for MF" but histologically benign was examined in 1 paper looking at cases of T-cell-rich borreliosis. 36 One paper examined clone comparisons in both MF and inflammatory dermatoses, where the clones in the cases of MF were known; this paper also examined cases in which patients with a prior history of MF Unique participants/total responses = 133 n % Call the clinician 12 9
Assess based on the histologic features 39 29 Assess based on the histologic and immunohistochemical features 79 59 Immediately order T-cell or B-cell clonality assays 0 0
Immediately order T-cell and B-cell clonality assays 3 2. Not at all familiar, I refer these patients to someone else 11 14 7 . What is your experience in working up lymphoproliferative disorders from the pathology side?
Unique participants/total responses = 136 n % I am very familiar, can do this in my sleep 30 22 I am somewhat familiar 92 68
Are you kidding! I send these things out to someone else 14 10 8. How much do you rely on histologic features to make the diagnosis of lymphoma?
Unique participants/total responses = 135 n % "In the vast majority of cases (especially mycosis fungoides), I do not need anything else (other than histology) to make the diagnosis" Unique participants/total responses = 144 n % "Yes, lots of exposure" 79 55
Some exposure 63 44 No exposure at all 2 1.4
(Continues) developed a new lesion. 52 One paper examined folliculotropic MF. 44 One paper examined secondary cutaneous involvement by systemic T-cell lymphomas in the context of a comparative study. 56 
| ASDP audience responses
The number of survey respondents ranged from 80 to 144 (average response rate 123/144, 85%) ( Unique participants/total responses = 130 n % Almost always 37 29 More than half of the time 18 14 Less than half of the time 24 19 Rarely 51 39
11. Do you order clonality assays when you think it is appropriate based on the information you have from the requisition, histologic features, and laboratory information system or do you allow for clinician decision-making by adding a comment in the report?
Unique participants/total responses = 118 n % Order when I think it is appropriate 60 51
Varies by case 37 31
Allow for clinician decision-making by adding comment 21 18 12. How much do you rely on immunohistochemical features to make the diagnosis of lymphoma?
Unique participants/total responses = 125 n % I always order immunohistochemical studies on every case of suspicious lymphoid infiltrates as they are an important adjunct 
52,58
Similarly, significant overlap can occur between cutaneous low grade, early B-cell lymphomas and CLHs that are B-cell-rich, and this can pose problems for the definitive diagnosis of B-cell lymphoma in the skin. 11, 16, 70, 71 In the case of earlier iterations of PCR, poor selection of primers as well as somatic hypermutation involving the IgH locus-posed problems of low sensitivity. 72 Some of these challenges have been overcome by establishment and publication of a standardized group of primers and protocols (the BIOMED-2 protocols and primers) to address both T-cell and B-cell clonality assays. 16, 52 Examination and interpretation of oligoclonal bands is an important aspect of clonality assessment in cutaneous LPD (and LPDs in general). While the use of standardized primers and protocols has decreased interobserver variability in determining threshold levels for monoclonal peak interpretation, it has not completely eliminated this problem. 73 For example, output of TCR gamma assays is dependent Clinically and histologically concerning for FCL 7
Clinically benign but histologically concerning for FCL 6
Clinically benign but histologically concerning for MZL 10
Clinically concerning for lymphoma but histologically benign 0 
